#BEGIN_DRUGCARD DB00254

# AHFS_Codes:
08:12.24
52:04.04

# ATC_Codes:
A01AB22
J01AA02

# Absorption:
Completely absorbed following oral administration.

# Biotransformation:
Hepatic

# Brand_Mixtures:
Not Available

# Brand_Names:
Alti-Doxycycline
Apo-Doxy
Atridox
Doryx
Doxy 100
Doxy-Caps
Doxy-Lemmon
Doxychel
Doxychel Hyclate
Doxycin
Doxylin
Doxytec
Jenacyclin
Monodox
Novo-Doxylin
Nu-Doxycycline
Oracea
Periostat
Supracyclin
Vibra-Tabs
Vibramycin

# CAS_Registry_Number:
564-25-0

# ChEBI_ID:
50845

# Chemical_Formula:
C22H24N2O8

# Chemical_IUPAC_Name:
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
742562

# Description:
A synthetic tetracycline derivative with similar antimicrobial activity. Animal studies suggest that it may cause less tooth staining than other tetracyclines. It is used in some areas for the treatment of chloroquine-resistant falciparum malaria (malaria, falciparum). [PubChem]

# Dosage_Forms:
Capsule	Oral
Gel, metered	Periodontal
Tablet	Oral

# Drug_Category:
Anti-Bacterial Agents
Antimalarials
Tetracyclines

# Drug_Interactions:
Acenocoumarol	The tetracycline, doxycycline, may increase the anticoagulant effect of acenocoumarol.
Acitretin	Increased risk of intracranial hypertension
Aluminium	Formation of non-absorbable complexes
Amobarbital	The anticonvulsant, amobarbital, decreases the effect of doxycycline.
Amoxicillin	Possible antagonism of action
Ampicillin	Possible antagonism of action
Anisindione	The tetracycline, doxycycline, may increase the anticoagulant effect of anisindione.
Aprobarbital	The anticonvulsant, aprobarbital, decreases the effect of doxycycline.
Attapulgite	Formation of non-absorbable complexes
Azlocillin	Possible antagonism of action
Aztreonam	Possible antagonism of action
Bacampicillin	Possible antagonism of action
Bexarotene	Tetracycline derivatives like doxycycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).
Butabarbital	The anticonvulsant, butabarbital, decreases the effect of doxycycline.
Butalbital	The anticonvulsant, butalbital, decreases the effect of doxycycline.
Butethal	The anticonvulsant, butethal, decreases the effect of doxycycline.
Calcium	Formation of non-absorbable complexes
Calcium Acetate	Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as doxycycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
Calcium Chloride	Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as doxycycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
Carbamazepine	The anticonvulsant, carbamazepine, may decrease the therapeutic effect of doxycycline.
Carbenicillin	Possible antagonism of action
Clavulanate	Possible antagonism of action
Cloxacillin	Possible antagonism of action
Colesevelam	Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
Cyclacillin	Possible antagonism of action
Dicloxacillin	Possible antagonism of action
Dicumarol	The tetracycline, doxycycline, may increase the anticoagulant effect of dicumarol.
Dihydroquinidine barbiturate	The anticonvulsant, dihydroquinidine barbiturate, decreases the effect of doxycycline.
Ethinyl Estradiol	Doxycycline may decrease the contraceptive effect of ethinyl estradiol.
Ethotoin	The anticonvulsant, ethotoin, decreases the effect of doxycycline.
Etretinate	Increased risk of intracranial hypertension
Flucloxacillin	Possible antagonism of action
Fosphenytoin	The anticonvulsant, fosphenytoin, decreases the effect of doxycycline.
Heptabarbital	The anticonvulsant, heptabarbital, decreases the effect of doxycycline.
Hetacillin	Possible antagonism of action
Hexobarbital	The anticonvulsant, hexobarbital, decreases the effect of doxycycline.
Iron	Formation of non-absorbable complexes
Iron Dextran	Formation of non-absorbable complexes
Isotretinoin	Increased risk of intracranial hypertension
Magnesium	Formation of non-absorbable complexes
Magnesium oxide	Formation of non-absorbable complexes
Mephenytoin	The anticonvulsant, mephenytoin, decreases the effect of doxycycline.
Mestranol	This anti-infectious agent could decrease the effect of the oral contraceptive
Methohexital	The anticonvulsant, methohexital, decreases the effect of doxycycline.
Methotrexate	The tetracycline, doxycycline, may increase methotrexate toxicity.
Methylphenobarbital	The anticonvulsant, methylphenobarbital, decreases the effect of doxycycline.
Meticillin	Possible antagonism of action
Mezlocillin	Possible antagonism of action
Nafcillin	Possible antagonism of action
Oxacillin	Possible antagonism of action
Penicillin G	Possible antagonism of action
Penicillin V	Possible antagonism of action
Pentobarbital	The anticonvulsant, pentobarbital, decreases the effect of doxycycline.
Phenobarbital	The anticonvulsant, phenobarbital, may decrease the therapeutic effect of doxycycline.
Phenytoin	The anticonvulsant, phenytoin, may decrease the effect of doxycycline.
Piperacillin	Possible antagonism of action
Pivampicillin	Possible antagonism of action
Pivmecillinam	Possible antagonism of action
Primidone	The anticonvulsant, primidone, decreases the effect of doxycycline.
Quinidine barbiturate	The anticonvulsant, quinidine barbiturate, decreases the effect of doxycycline.
Rifabutin	The rifamycin decreases the effect of doxycycline
Rifampin	The rifamycin decreases the effect of doxycycline
Secobarbital	The anticonvulsant , secobarbital, decreases the effect of doxycycline.
Talbutal	The anticonvulsant, talbutal, decreases the effect of doxycycline.
Tamsulosin	Doxycycline, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Doxycycline is initiated, discontinued, or dose changed.
Tazobactam	Possible antagonism of action
Thiopental	Thiopental may decrease the serum levels of Doxycycline. A reduction in antimicrobial effects may occur. An alternative antibiotic may be considered.
Ticarcillin	Doxycycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Doxycycline.
Tolterodine	Doxycycline may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
Tretinoin	Doxycycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided.
Warfarin	The tetracycline, doxycycline, may increase the anticoagulant effect of warfarin.
Zinc	Formation of non-absorbable complexes

# Drug_Reference:
12684759	Hoerauf A, Mand S, Fischer K, Kruppa T, Marfo-Debrekyei Y, Debrah AY, Pfarr KM, Adjei O, Buttner DW: Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Med Microbiol Immunol. 2003 Nov;192(4):211-6. Epub 2003 Mar 5.
15964448	Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S, Hoerauf A: Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet. 2005 Jun 18-24;365(9477):2116-21.
16940111	Dahl EL, Shock JL, Shenai BR, Gut J, DeRisi JL, Rosenthal PJ: Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother. 2006 Sep;50(9):3124-31.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.02

# Experimental_Logs:
-2.87

# Experimental_Water_Solubility:
630 mg/L (at 25 °C)

# Food_Interactions:
Avoid alcohol.
Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
Take with a full glass of water Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.

# GenBank_ID:
Not Available

# Generic_Name:
Doxycycline

# HET_ID:
Not Available

# Half_Life:
18-22 hours

# InChI_Identifier:
InChI=1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25,27-29,32H,1-3H3,(H2,23,31)/t7-,10+,14+,15-,17-,22-/m0/s1

# InChI_Key:
InChIKey=JBIWCJUYHHGXTC-AKNGSSGZSA-N

# Indication:
Doxycycline is indicated for use in respiratory tract infections caused by Mycoplasma pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae, Legionella spp., or Klebsiella spp. It is also used for prophylaxis of malaria. Doxycycline is indicated for a variety of bacterial infections, from Mycobacterium fortuitum and M. marinum, to susceptible E. coli and Brucella spp. It can be used as an alternative to treating plague, tetanus, Campylobacter fetus

# KEGG_Compound_ID:
C06973

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
254

# Mechanism_Of_Action:
Doxycycline, like minocycline, is lipophilic and can pass through the lipid bilayer of bacteria. Doxycycline reversibly binds to the 30 S ribosomal subunits and possibly the 50S ribosomal subunit(s), blocking the binding of aminoacyl tRNA to the mRNA and inhibiting bacterial protein synthesis. Doxycycline prevents the normal function of the apicoplast of Plasmodium falciparum, a malaria causing organism.

# Melting_Point:
201 °C

# Molecular_Weight_Avg:
444.4346

# Molecular_Weight_Mono:
444.153265754

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
1P87

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Doxycycline Pathway	SMP00291

# PharmGKB_ID:
PA449415

# Pharmacology:
Doxycycline, a long-acting tetracycline derived from oxytetracycline, is used to inhibit bacterial protein synthesis and treat non-gonococcal urethritis and cervicitis, exacerbations of bronchitis in patients with COPD, and adult periodontitis.

# Predicted_LogP_Hydrophobicity:
-0.72

# Predicted_LogS:
-2.9

# Predicted_Water_Solubility:
6.30e-01 g/l

# Primary_Accession_No:
DB00254

# Protein_Binding:
>90%

# PubChem_Compound_ID:
5281011

# PubChem_Substance_ID:
46506491

# RxList_Link:
http://www.rxlist.com/cgi/generic/doxycyc.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00597

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Doxcycline anhydrous
Doxycycline Hyclate
Doxycycline Monohydrate
Doxytetracycline

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose include anorexia, nausea, diarrhoea, glossitis, dysphagia, enterocolitis and inflammatory lesions (with monilial overgrowth) in the anogenital region, skin reactions such as maculopapular and erythematous rashes, exfoliative dermatitis, photosensitivity, hypersensitivity reactions such as urticaria, angioneurotic oedema, anaphylaxis, anaphyl-actoid purpura, pericarditis, and exacerbation of systemic lupus erythematosus, benign intracranial hypertension in adults disappearing on discontinuation of the medicine, haematologic abnormalities such as haemolytic anaemia, thrombocytopenia, neutropenia, and eosinophilia. LD<sub>50</sub>=262 mg/kg (I.P. in rat).

# Update_Date:
2013-02-08 16:19:12 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Doxycycline

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_1_ID:
4512

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P08684

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
20592239	Griffin MO, Fricovsky E, Ceballos G, Villarreal F: Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol. 2010 Sep;299(3):C539-48. Epub 2010 Jun 30.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X02130

# Drug_Target_1_GenBank_ID_Protein:
535073

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
rpsI

# Drug_Target_1_Gene_Sequence:
>393 bp
ATGGCTGAAAATCAATACTACGGCACTGGTCGCCGCAAAAGTTCCGCAGCTCGCGTTTTC
ATCAAACCGGGCAACGGTAAAATCGTAATCAACCAACGTTCTCTGGAACAGTACTTCGGT
CGTGAAACTGCCCGCATGGTAGTTCGTCAGCCGCTGGAACTGGTCGACATGGTTGAGAAA
CTGGACCTGTACATCACCGTTAAAGGTGGTGGTATCTCTGGTCAGGCTGGTGCGATCCGT
CACGGTATCACCCGCGCTCTGATGGAATACGACGAGTCCCTGCGTTCTGAACTGCGTAAA
GCTGGCTTCGTTACTCGTGACGCTCGTCAGGTTGAACGTAAGAAAGTCGGTCTGCGTAAA
GCACGTCGTCGTCCGCAGTTCTCCAAACGTTAA

# Drug_Target_1_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_1_General_References:
10094780	Arnold RJ, Reilly JP: Observation of Escherichia coli ribosomal proteins and their posttranslational modifications by mass spectrometry. Anal Biochem. 1999 Apr 10;269(1):105-12.
1091515	Chen R, Wittmann-Liebold B: The primary structure of protein S9 from the 30S subunit of Escherichia coli ribosomes. FEBS Lett. 1975 Mar 15;52(1):139-40.
12244297	Tung CS, Joseph S, Sanbonmatsu KY: All-atom homology model of the Escherichia coli 30S ribosomal subunit. Nat Struct Biol. 2002 Oct;9(10):750-5.
12809609	Gao H, Sengupta J, Valle M, Korostelev A, Eswar N, Stagg SM, Van Roey P, Agrawal RK, Harvey SC, Sali A, Chapman MS, Frank J: Study of the structural dynamics of the E coli 70S ribosome using real-space refinement. Cell. 2003 Jun 13;113(6):789-801.
3884974	Isono S, Thamm S, Kitakawa M, Isono K: Cloning and nucleotide sequencing of the genes for ribosomal proteins S9 (rpsI) and L13 (rplM) of Escherichia coli. Mol Gen Genet. 1985;198(2):279-82.
4346030	Marsh RC, Parmeggiani A: Requirement of proteins S5 and S9 from 30S subunits for the ribosome-dependent GTPase activity of elongation factor G. Proc Natl Acad Sci U S A. 1973 Jan;70(1):151-5.
7556101	Urlaub H, Kruft V, Bischof O, Muller EC, Wittmann-Liebold B: Protein-rRNA binding features and their structural and functional implications in ribosomes as determined by cross-linking studies. EMBO J. 1995 Sep 15;14(18):4578-88.
8524654	Osswald M, Doring T, Brimacombe R: The ribosomal neighbourhood of the central fold of tRNA: cross-links from position 47 of tRNA located at the A, P or E site. Nucleic Acids Res. 1995 Nov 25;23(22):4635-41.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
140

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
14725

# Drug_Target_1_Name:
30S ribosomal protein S9

# Drug_Target_1_Number_of_Residues:
129

# Drug_Target_1_PDB_ID:
1P87

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00380	Ribosomal_S9

# Drug_Target_1_Protein_Sequence:
>30S ribosomal protein S9
AENQYYGTGRRKSSAARVFIKPGNGKIVINQRSLEQYFGRETARMVVRQPLELVDMVEKL
DLYITVKGGGISGQAGAIRHGITRALMEYDESLRSELRKAGFVTRDARQVERKKVGLRKA
RRRPQFSKR

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
The C-terminal tail plays a role in the affinity of the 30S P site for different tRNAs. Mutations that decrease this affinity are suppressed in the 70S ribosome

# Drug_Target_1_SwissProt_ID:
P0A7X3

# Drug_Target_1_SwissProt_Name:
RS9_ECOLI

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
11.52

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasmic

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
20592239	Griffin MO, Fricovsky E, Ceballos G, Villarreal F: Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol. 2010 Sep;299(3):C539-48. Epub 2010 Jun 30.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
X02543

# Drug_Target_2_GenBank_ID_Protein:
42798

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
rpsD

# Drug_Target_2_Gene_Sequence:
>621 bp
ATGGCAAGATATTTGGGTCCTAAGCTCAAGCTGAGCCGTCGTGAGGGCACCGACTTATTC
CTTAAGTCTGGCGTTCGCGCGATCGATACCAAGTGTAAAATTGAACAAGCTCCTGGCCAG
CACGGTGCGCGTAAACCGCGTCTGTCTGACTATGGTGTGCAGTTGCGTGAAAAGCAAAAA
GTTCGCCGTATCTATGGTGTGCTGGAGCGTCAGTTCCGTAACTACTACAAAGAAGCAGCA
CGTCTGAAAGGCAACACCGGTGAAAACCTGTTGGCTCTGCTGGAAGGTCGTCTGGACAAC
GTTGTATACCGTATGGGCTTCGGTGCCACTCGTGCAGAAGCACGTCAGCTGGTTAGCCAT
AAAGCAATTATGGTAAACGGTCGTGTTGTTAACATCGCTTCTTATCAGGTTAGTCCGAAT
GACGTTGTAAGCATTCGTGAGAAAGCGAAGAAGCAGTCTCGCGTGAAAGCCGCTCTGGAG
CTGGCTGAGCAGCGTGAAAAGCCAACCTGGCTGGAAGTTGATGCTGGCAAGATGGAAGGT
ACGTTTAAGCGTAAGCCGGAGCGTTCTGATCTGTCTGCGGACATTAACGAACACCTGATC
GTCGAGCTTTACTCCAAGTAA

# Drug_Target_2_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_2_General_References:
10094780	Arnold RJ, Reilly JP: Observation of Escherichia coli ribosomal proteins and their posttranslational modifications by mass spectrometry. Anal Biochem. 1999 Apr 10;269(1):105-12.
1100394	Schiltz E, Reinbolt J: Determination of the complete amino-acid sequence of protein S4 from Escherichia coli ribosomes. Eur J Biochem. 1975 Aug 15;56(2):467-81.
11018284	Dahlgren A, Ryden-Aulin M: A novel mutation in ribosomal protein S4 that affects the function of a mutated RF1. Biochimie. 2000 Aug;82(8):683-91.
11447122	Torres M, Condon C, Balada JM, Squires C, Squires CL: Ribosomal protein S4 is a transcription factor with properties remarkably similar to NusA, a protein involved in both non-ribosomal and ribosomal RNA antitermination. EMBO J. 2001 Jul 16;20(14):3811-20.
12244297	Tung CS, Joseph S, Sanbonmatsu KY: All-atom homology model of the Escherichia coli 30S ribosomal subunit. Nat Struct Biol. 2002 Oct;9(10):750-5.
12809609	Gao H, Sengupta J, Valle M, Korostelev A, Eswar N, Stagg SM, Van Roey P, Agrawal RK, Harvey SC, Sali A, Chapman MS, Frank J: Study of the structural dynamics of the E coli 70S ribosome using real-space refinement. Cell. 2003 Jun 13;113(6):789-801.
2461734	Nowotny V, Nierhaus KH: Assembly of the 30S subunit from Escherichia coli ribosomes occurs via two assembly domains which are initiated by S4 and S7. Biochemistry. 1988 Sep 6;27(18):7051-5.
2477554	Allen PN, Noller HF: Mutations in ribosomal proteins S4 and S12 influence the higher order structure of 16 S ribosomal RNA. J Mol Biol. 1989 Aug 5;208(3):457-68.
2989779	Bedwell D, Davis G, Gosink M, Post L, Nomura M, Kestler H, Zengel JM, Lindahl L: Nucleotide sequence of the alpha ribosomal protein operon of Escherichia coli. Nucleic Acids Res. 1985 Jun 11;13(11):3891-903.
3309351	Thomas MS, Bedwell DM, Nomura M: Regulation of alpha operon gene expression in Escherichia coli. A novel form of translational coupling. J Mol Biol. 1987 Jul 20;196(2):333-45.
387752	Post LE, Nomura M: Nucleotide sequence of the intercistronic region preceding the gene for RNA polymerase subunit alpha in Escherichia coli. J Biol Chem. 1979 Nov 10;254(21):10604-6.
4587210	Reinbolt J, Schiltz E: The primary structure of ribosomal protein S4 from Escherichia coli. FEBS Lett. 1973 Nov 1;36(3):250-2.
7556101	Urlaub H, Kruft V, Bischof O, Muller EC, Wittmann-Liebold B: Protein-rRNA binding features and their structural and functional implications in ribosomes as determined by cross-linking studies. EMBO J. 1995 Sep 15;14(18):4578-88.
7559430	Baker AM, Draper DE: Messenger RNA recognition by fragments of ribosomal protein S4. J Biol Chem. 1995 Sep 29;270(39):22939-45.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9716382	Choi KM, Atkins JF, Gesteland RF, Brimacombe R: Flexibility of the nascent polypeptide chain within the ribosome--contacts from the peptide N-terminus to a specific region of the 30S subunit. Eur J Biochem. 1998 Jul 15;255(2):409-13.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
22

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
23338

# Drug_Target_2_Name:
30S ribosomal protein S4

# Drug_Target_2_Number_of_Residues:
205

# Drug_Target_2_PDB_ID:
1P87

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00163	Ribosomal_S4
PF01479	S4

# Drug_Target_2_Protein_Sequence:
>30S ribosomal protein S4
ARYLGPKLKLSRREGTDLFLKSGVRAIDTKCKIEQAPGQHGARKPRLSDYGVQLREKQKV
RRIYGVLERQFRNYYKEAARLKGNTGENLLALLEGRLDNVVYRMGFGATRAEARQLVSHK
AIMVNGRVVNIASYQVSPNDVVSIREKAKKQSRVKAALELAEQREKPTWLEVDAGKMEGT
FKRKPERSDLSADINEHLIVELYSK

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Also functions as a rho-dependent antiterminator of rRNA transcription, increasing the synthesis of rRNA under conditions of excess protein, allowing a more rapid return to homeostasis. Binds directly to RNA polymerase

# Drug_Target_2_SwissProt_ID:
P0A7V8

# Drug_Target_2_SwissProt_Name:
RS4_ECOLI

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
10.66

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasmic

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17122017	Kumar S, Kutlin A, Roblin P, Kohlhoff S, Bodetti T, Timms P, Hammerschlag MR: Isolation and antimicrobial susceptibilities of Chlamydial isolates from Western barred bandicoots. J Clin Microbiol. 2007 Feb;45(2):392-4. Epub 2006 Nov 22.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
17428623	Pringle M, Fellstrom C, Johansson KE: Decreased susceptibility to doxycycline associated with a 16S rRNA gene mutation in Brachyspira hyodysenteriae. Vet Microbiol. 2007 Jul 20;123(1-3):245-8. Epub 2007 Feb 25.
9661007	Ross JI, Eady EA, Cove JH, Cunliffe WJ: 16S rRNA mutation associated with tetracycline resistance in a gram-positive bacterium. Antimicrob Agents Chemother. 1998 Jul;42(7):1702-5.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
Not Available

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
Not Available

# Drug_Target_3_Gene_Sequence:
>16S rRNA sequence
AAATTGAAGAGTTTGATCATGGCTCAGATTGAACGCTGGCGGCAGGCCTAACACATGCAA
GTCGAACGGTAACAGGAAACAGCTTGCTGTTTCGCTGACGAGTGGCGGACGGGTGAGTAA
TGTCTGGGAAACTGCCTGATGGAGGGGGATAACTACTGGAAACGGTAGCTAATACCGCAT
AACGTCGCAAGACCAAAGAGGGGGACCCTCGGGCCTCTTGCCATCGGATGTGCCCAGATG
GGATTAGCTTGTTGGTGGGGTAACGGCTCACCAAGGCGACGATCCCTAGCTGGTCTGAGA
GGATGACCAGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGG
GGAATATTGCACAATGGGCGCAAGCCTGATGCAGCCATGCCGCGTGTATGAAGAAGGCCT
TCGGGTTGTAAAGTACTTTCAGCGGGGAGGAAGGGAGTAAAGTTAATACCTTTGCTCATT
GACGTTACCCGCAGAAGAAGCACCGGCTAACTCCGTGCCAGCAGCCGCGGTAATACGGAG
GGTGCAAGCGTTAATCGGAATTACTGGGCGTAAAGCGCACGCAGGCGGTTTGTTAAGTCA
GATGTGAAATCCCCGGGCTCAACCTGGGAACTGCATCTGATACTGGCAAGCTTGAGTCTC
GTAGAGGGGGGTAGAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACC
GGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCA
AACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGTCGACTTGGAGGTTGTGCC
CTTGAGGCGTGGCTTCCGGAGCTAACGCGTTAAGTCGACCGCCTGGGGAGTACGGCCGCA
AGGTTAAAACTCAAATGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAAT
TCGATGCAACGCGAAGAACCTTACCTGGTCTTGACATCCACGGAAGTTTTCAGAGATGAG
AATGTGCCTTCGGGAACCGTGAGACAGGTGCTGCATGGCTGTCGTCAGCTCGTGTTGTGA
AATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATCCTTTGTTGCCAGCGGTCCGGC
CGGGAACTCAAAGGAGACTGCCAGTGATAAACTGGAGGAAGGTGGGGATGACGTCAAGTC
ATCATGGCCCTTACGACCAGGGCTACACACGTGCTACAATGGCGCATACAAAGAGAAGCG
ACCTCGCGAGAGCAAGCGGACCTCATAAAGTGCGTCGTAGTCCGGATTGGAGTCTGCAAC
TCGACTCCATGAAGTCGGAATCGCTAGTAATCGTGGATCAGAATGCCACGGTGAATACGT
TCCCGGGCCTTGTACACACCGCCCGTCACACCATGGGAGTGGGTTGCAAAAGAAGTAGGT
AGCTTAACCTTCGGGAGGGCGCTTACCACTTTGTGATTCATGACTGGGGTGAAGTCGTAA
CAAGGTAACCGTAGGGGAACCTGCGGTTGGATCACCTCCTTA

# Drug_Target_3_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_3_General_References:
10194318	Gu XR, Gustafsson C, Ku J, Yu M, Santi DV: Identification of the 16S rRNA m5C967 methyltransferase from Escherichia coli. Biochemistry. 1999 Mar 30;38(13):4053-7.
12948628	Martin JF, Barreiro C, Gonzalez-Lavado E, Barriuso M: Ribosomal RNA and ribosomal proteins in corynebacteria. J Biotechnol. 2003 Sep 4;104(1-3):41-53.
1764510	Srivastava AK, Schlessinger D: Structure and organization of ribosomal DNA. Biochimie. 1991 Jun;73(6):631-8.
8177168	Gutell RR, Larsen N, Woese CR: Lessons from an evolving rRNA: 16S and 23S rRNA structures from a comparative perspective. Microbiol Rev. 1994 Mar;58(1):10-26.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
883

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
Not Available

# Drug_Target_3_Name:
16S rRNA

# Drug_Target_3_Number_of_Residues:
0

# Drug_Target_3_PDB_ID:
1EMI

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
Not Available

# Drug_Target_3_Protein_Sequence:
Not Available

# Drug_Target_3_Reaction:
rRNA + mRNA + Amino Acids = Polypeptide

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
In prokaryotes, the 16S rRNA is essential for recognizing the 5' end of mRNA and hence positioning it correctly on the ribosome. The 16S rRNA has a characteristic secondary structure in which half of the nucleotides are base-paired. The 16S rRNA sequence has been highly conserved and is often used for evolutionary and species comparative analysis.

# Drug_Target_3_SwissProt_ID:
Not Available

# Drug_Target_3_SwissProt_Name:
Not Available

# Drug_Target_3_Synonyms:
16S ribosomal ribonucleic acid

# Drug_Target_3_Theoretical_pI:
Not Available

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB00254
